Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$0.15
EPS est.
$-0.38
EPS surprise
+139.27%
1-day move
-0.27%
Apellis Pharmaceuticals reported a significant earnings surprise with an EPS of $0.15, compared to the expected loss. However, the stock reacted negatively, declining by 0.27%. The lack of revenue figures and guidance may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.15 | $-0.36 | +139.27% |
| Revenue | — | $203M | — |
No transcript is on record, and the analysis is based on numerical results only.
Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases. Operating in the health care sector, it aims to address significant unmet medical needs, particularly in autoimmune and hematologic disorders.
Last quarter
In the last quarter, Apellis reported an EPS of $0.47, significantly beating expectations. However, the stock price fell the next day, indicating mixed investor sentiment.
Management promises and guidance
EPS beat streak
4Q
EPS beat rate
75%
Avg EPS surprise
+40.64%
Avg 1-day reaction
-4.40%
Analysts expect Apellis to report a loss this quarter, but there is hope for revenue growth as the company continues to launch new products.
Bull case
If Apellis can exceed revenue expectations and show a path to profitability, it could boost investor confidence and drive the stock higher.
Bear case
If the company fails to meet revenue estimates or reports wider losses, it could lead to further declines in stock price.
Key metrics to watch
EPS
$-0.36Earnings per share (EPS) is a key indicator of profitability, and investors will be looking for signs of improvement or continued losses.
Revenue
$203MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will revenue exceed the consensus estimate of $203M?
Revenue performance is critical for assessing the company's growth trajectory and market acceptance of its products.
Q2
What specific plans does management have to reduce losses this quarter?
Understanding management's strategy for improving profitability will be key for investor confidence.
Why consensus could be wrong
The consensus may underestimate the potential for revenue growth driven by recent product launches, which could lead to a stronger performance than expected.
Supporting evidence
The company has a history of beating EPS estimates, which could translate to better-than-expected revenue.
Options pricing suggests a lower expected move compared to historical averages, indicating potential for a surprise.
Key risk
If revenue comes in above $203M, it could shift investor sentiment significantly.
Pre-commit to what would confirm each case.
The market is weighing the potential for revenue growth against the backdrop of ongoing losses, making this quarter's performance critical.
Bull confirmed if
Revenue growth exceeding $203M with a clear path to reducing losses.
Bear confirmed if
Revenue falling below $170M or wider losses than expected.
What the market is pricing for the move.
Implied Move
±5.72%
Historical Avg
±8.8%
The options market is pricing in a moderate move around the earnings report, suggesting uncertainty about the results.
Options are pricing ±1.2% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing cheap.
30d HV
248.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Apellis beats expectations, history suggests the stock could rise by around 10% on the first day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of around 3.8%, reflecting ongoing concerns about profitability.
The lines on the call that would change the story.
—
Est. EPS
$-0.76
Est. Rev
$192M
Impl. Move
±7.5%